Avonex® IFN-β-1a im. weekly RRMS and 'early therapy' in patients with an initial demyelinating event and high risk of occurrence of clinically definite MS Rebif® IFN-β-1a sc. three times a ...

Data from a phase 2 trial of Roche's oral BTK inhibitor fenebrutinib have shown "near-complete suppression" of disease activity and disability progression in relapsing multiple sclerosis (MS).

A Phase 2 clinical trial testing obexelimab in adults with relapsing types of multiple sclerosis is now recruiting ...

RRMS is the most common type of multiple sclerosis ... including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.

Multiple sclerosis (MS) is a common immune-mediated ... primary progressive, and progressive relapsing MS. A clinically isolated syndrome (CIS) is a first neurological episode lasting more than ...

Under the terms of the agreement, TG Therapeutics obtains non-exclusive research, clinical and commercial rights to use MaxCyte’s Flow Electroporation ® technology and ExPERT™ platform. In return, ...

Immunic (NASDAQ:IMUX – Get Free Report) was downgraded by equities research analysts at StockNews.com from a “hold” rating to ...

WHEN life gave Lina Nielsen lemons, she sprinted straight to the Olympics.  The 28-year-old was diagnosed with multiple sclerosis at 17 years old, leaving her terrified of disability. Doctors gave ...

Bleakley Financial Group LLC purchased a new stake in TG Therapeutics, Inc. (NASDAQ:TGTX – Free Report) in the 4th quarter, Holdings Channel.com reports. The fund purchased 8,140 shares of the ...

In a challenging market environment, Immunic, Inc. (NASDAQ:IMUX) stock has recorded a new 52-week low, dipping to $0.92. The biopharmaceutical company, which focuses on developing treatments for ...